|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 21:42 JST
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
达丰设备服务有限公司 公布2024/25中期业绩
Nov 22, 2024 19:35 HKT/SGT
|
|
|
達豐設備服務有限公司 公佈2024/25中期業績
Nov 22, 2024 19:18 HKT/SGT
|
|
|
透雲生物萊茵衣藻獲國家衛健委新用途許可
Nov 22, 2024 14:42 HKT/SGT
|
|
|
透云生物莱茵衣藻获国家卫健委新用途许可
Nov 22, 2024 14:41 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 12:00: JST
|
|
|
Daeshin MC Co., Ltd.は、産業現場から公共施設まで快適な室内環境を作り出すクリーンソリューションを発表
Nov 22, 2024 12:00: JST
|
|
|
三菱重工、新たな防衛輸送用「機動舟艇」に搭載するウォータージェット推進装置の供給へ
Nov 22, 2024 11:45: JST
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
雅各臣公佈二零二五財年中期業績 持續經營業務溢利飈升44.2%
Nov 22, 2024 10:00 HKT/SGT
|
|
|
アレス・マネジメント、東京オフィス開設でアジア事業を拡充
Nov 22, 2024 09:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
